

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number  
**WO 2004/076449 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 453/00**,  
453/02

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/US2004/005044

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 20 February 2004 (20.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/372,642 21 February 2003 (21.02.2003) US

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,  
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,  
LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG)
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations

(71) Applicant (for all designated States except US): **TARGA-  
CEPT, INC.** [US/US]; 200 East First Street, Suite 300,  
Winston-Salem, NC 27101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MAZUROV, Ana-  
toly, A.** [UA/US]; 3704 Timberoak Drive, Greensboro, NC  
27410 (US). **KLUCIK, Jozef** [US/US]; 9071 Chancer-  
wood Drive, Rural Hall, NC 27045 (US). **MIAO, Lan**  
[CN/US]; 226 Ferry Road, Advance, NC 27006 (US).  
**SEAMANS, Angela, S.** [US/US]; 5211 Cotton Mill  
Lane, Jamestown, NC 27282 (US). **PHILLIPS, Teresa,  
Youngpeter** [US/US]; 1230 Tarrant Road, Greensboro,  
NC 27409 (US). **SCHMITT, Jeffrey, Daniel** [US/US];  
5619 Pineview Drive, Winston-Salem, NC 27409 (US).  
**MILLER, Craig, Harrison** [US/US]; 1564 Sharon Road,  
Winston-salem, NC 27103 (US).

(74) Agent: **MASSEY, Carl, B., Jr.**; Womble Carlyle San-  
dridge & Rice, PLLC, P.O. Box 7037, Atlanta, GA 30357  
(US).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

(88) Date of publication of the international search report:

18 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the com-  
pounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes,  
or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and  
5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is  
a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality.  
The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the  $\alpha 7$  nAChR subtype, and are useful  
towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating  
conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neu-  
rotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess  
neovascularization, such as that associated with tumor growth.

WO 2004/076449 A3